Cancer Stem Cells Market Growth 2022-2030: Increasing Acceptance for Stem Cell Therapies Is Stimulating the Industry

The Global Cancer Stem Cells Market size is estimated to reach USD 2.98 Billion from USD 1.14 Billion in 2021, delivering a growth rate of 11% through 2030, according to a new report by Reports and Data. The demand for cancer stem cell markers is exponentially growing on account of growing public awareness regarding the therapeutic strength of products, public-private investments in drug development, and the development of a regulatory framework for cancer stem cell therapeutics.

Access Free sample PDF Copy of the Report @

The treatment of cancer can damage the hematopoietic stem cells in the body. The hematopoietic stem cells are stem cells that turn into blood cells. Stem cell transplant helps with blood-forming stem cells in patients that have undergone a high dosage of radiation or chemotherapy and have damaged stem cells as a reaction. Embryonic stem cells are the main source of stem cells for therapeutic purposes due to high potency and their indefinite lifespan. The growing prevalence of the deadly disease will supplement the market share over the forecast period. According to the World Health Organization, there were nearly 18.1 million new cancer cases and 9.6 million deaths in 2018. Cancer Research UK has predicted there will be 27.5 million new cases each year globally by 2040. 

The increasing morbidity and mortality rates of cancer have led to rising funding from the government along with growth in many research activities to develop stem cell therapies. Several industry players are supported by government funding for the development of these therapies. For instance, Stemcell Technologies, the biggest biotechnology firm, accepted USD 45 million from a joint venture of British Columbia and the Government of Canada in April 2018 for the expansion of technologies to assist clinical trials in the field of tissue engineering, cell therapy, immunotherapy, reformative medicine, and gene therapy to treat cancer and other diseases. These strategies by the industry players will bolster the industry growth through 2030.

Competitive Landscape:

The global market comprises various market players operating at regional and global levels. These key players are adopting various strategies such as R&D investments, license agreements, partnerships, merger and acquisitions, collaborations, and joint ventures to gain robust footing in the market.

Top Companies Profiled in the Report:


AbbVie, Inc., Thermo Fisher Scientific, Inc., Bionomics, Merck KGaA, Miltenyi Biotec, LONZA, Stemline Therapeutics, Inc., Irvine Scientific, MacroGenics, Inc., and PromoCell GmbH, among others.

To know more about the report, visit @

Further key findings from the report suggest:

  • Based on treatment type, the autologous stem cell therapy segment is forecast to register the highest CAGR of 8.6% through 2030 on account of the low risk of complications associated with treatment. Additionally, the improved survival rate of patients, no requirement for the identification of an HLA-matched donor, affordability, and low risk of graft-versus-host diseases are some other factors bolstering segmental growth.
  • Based on disease type, the lung cancer segment is estimated to account for the majority of the cancer stem cells market revenue share. According to the WHO, approximately 228.150 new cases of lung cancer were detected in 2019 in the U.S. alone, while 142,670 deaths occurred in the same year due to the disease. The rising trend of smoking cigarettes will foster market share over the forecast period.
  • In terms of end-use, the hospital and surgical centers are estimated to account for 38.2% of the market revenue share through 2030.
  • In the regional landscape, North America dominates the market share due to access to the latest advanced technologies, substantial investment by the public and private sectors, and strong economic growth. The availability of state-of-the-art research infrastructure, and rise in R&D initiatives to develop therapeutic options for chronic diseases, will bolster regional market growth.
  • Asia Pacific region is estimated to account for 25.2% of the market share by 2030 due to the highest prevalence of cancer, creating a huge demand for stem cell therapies in the region. 
  • Europe is estimated to register a CAGR 11.2% through 2030 on account of supportive government initiatives and funding for stem cell R&D activities in the region.
  • In January 2020, LabCorp adopted the Ion Torrent Genexus System and Oncomine Precision Assay by Thermo Fisher Scientific for use in R&D of companion diagnostics and other applications in oncology and precision medicine.

Download Summary @

Cancer Stem Cells Market Segmentation:

Cancer Type Outlook (Revenue, USD Billion; 2019-2030)

  • Chronic lymphocytic leukemia (CLL)
  • Acute leukemia
  • Aplastic anemia
  • Osteopetrosis
  • Others

Transplantation Outlook (Revenue, USD Billion; 2019-2030)

  • Allogeneic stem cell therapy
  • Autologous stem cell therapy

Regional Outlook:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, U.K., Italy, France, BENELUX, Rest of Europe)
  • Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
  • Latin America (Brazil, Rest of LATAM)
  • Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Ask for Customize Research Report @

This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the market’s future growth.

Explore Latest Trending Research Reports By Reports and Data's:

Bloodstream Infection Testing Market Analysis Report By Product (Consumables, Instruments, Software), By Technique (Conventional, Automated), By Technology (Culture-based, Molecular Proteomic), By Application (Bacterial, Fungal, Mycobacterial), By End Use (Hospital Laboratories, Reference Laboratories, Academic Research Laboratories, and Others) and Segment Forecasts for 2016 - 2026

Optical Microscope Market Size, Share, Demand By Product (Digital Microscopes, Stereo Microscopes, Inverted Microscopes, Others), By End-user (Hospitals & Clinics, Academic & Research Institutes, Diagnostics Laboratories, Pharmaceutical & Biotechnology Companies, Others), By Region, Competitive Strategies and Segment Forecasts, 2016-2025

Positron Emission Tomography Market Size, Share & Trends Analysis Report By Type (Full-Ring PET Scanners, Partial Ring PET Scanners), By Application, By End-user, By Region, Competitive Strategies and Segment Forecasts to 2016-2026

Colorectal Cancer Market Size, Share And Industry Analysis By Product-based (In situ Hybridization, Flow Cytometry, Next-generation Sequencing, Microarrays, Chemotherapy, Immunotherapy, Targeted therapy), By Procedure (Biopsy, Mammography, Colostomy, Sigmoidoscopy, MRI) And Region, Segment Forecasts To 2026

Erythropoietin (EPO) Drugs Market Size, Share & Trends Analysis Report By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa & Others), By Application, By Region, Competitive Strategies and Segment Forecasts to 2016-2026


About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W
Head of Business Development
Reports And Data | Web:
Direct Line: +1-212-710-1370
LinkedIn | Twitter | Blogs


Back to news